Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5884 in Stable Coronary Heart Disease
NCT03351738Phase 2Completed
- Sponsor
- MedImmune
- Start
- Dec 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MEDI5884 in coronary heart disease (CHD) (6 arms), sponsored by MedImmune. Primary endpoints: Treatment Emergent Adverse Events, Clinically Important Changes in Electrocardiograms and 2 more. Started Dec 2017; status: completed.
02
Drugs
MEDI5884
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT03351738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351738.